首页|青藤碱-硝酸酯偶联物的合成及体外抗肿瘤活性筛选

青藤碱-硝酸酯偶联物的合成及体外抗肿瘤活性筛选

扫码查看
目的:为寻找青藤碱有效的结构修饰方法以挖掘其抗肿瘤作用.方法:基于对母体结构特点的剖析设计合成了一系列青藤碱-硝酸酯偶联物,所合成偶联物的结构经IR光谱、1 H-NMR、13 C-NMR和高分辨质谱确证.运用四甲基偶氮唑蓝(MTT)法筛选偶联物对人源5 种肿瘤细胞(宫颈癌Hela细胞、肺癌A549细胞、肝癌HepG2 细胞、乳腺癌MCF-7 细胞和结肠癌HT-29 细胞)体外抗肿瘤活性.结果:共设计合成了9个青藤碱-硝酸酯偶联物.相比其他系列的偶联物,6-苯腙基青藤碱-硝酸酯偶联物体外抗肿瘤作用更为突出,其中衍生物10d对Hela,MCF-7 及HT-29 细胞株的抑制作用均优于阳性对照药顺铂,IC50分别为(9.72±0.53),(15.46±8.16),(8.19±1.05)μmol·L-1.结论:衍生物10d对多种待测肿瘤细胞有良好的体外抗肿瘤活性,可作为抗肿瘤的前体药物分子,值得继续开展进一步的研究.
Synthesis and in vitro anti-tumor effects screening of sinomenine-nitrate conjugates
Objective:To find effective structural modification methods for discovering the anti-tumor activity of sinomenine.Methods:Based on the structural characteristics of sinomenine,a series of sinomenine-nitrate conjugates were designed and synthesized.The structures of all these compounds were confirmed by infrared spectroscopy,nuclear magnetic resonance hydrogen spectroscopy,nuclear magnetic resonance carbon spectroscopy and high-resolution mass spectrometry.MTT assay was used to test the inhibitory effects of sinomenine-nitrate conjugates on the proliferation of human tumor cells(cervical cancer Hela cells,lung cancer A549 cells,liver cancer HepG2 cells,breast cancer MCF-7 cells and colon cancer HT-29 cells)in vitro.Results:Nine nitrate derivatives were effectively synthesized.Compared with other conjugates,6-phenylhydrazone sinomenine-nitrate conjugates showed outstanding anti-tumor activity in vitro.The anti-proliferation ability of derivative 10d on Hela,MCF-7 and HT-29 was better than that of the positive drug cisplatin,with IC50 being(9.72±0.53),(15.46±8.16),(8.19±1.05)μmol·L-1,respectively.Conclusion:Compound10d has good anti-tumor activity against various tested tumor cells and can be used as a precursor molecule for anti-cancer drugs,which needs to be further studied.

sinomeninestructural modificationnitrateconjugateanti-tumor

周慧娴、余梓楷、吴志文、朱祖昌、何宝恩、王涛

展开 >

广州中医药大学中药学院,广州 510006

珠海联邦制药有限公司纯化研发中心,珠海 519040

青藤碱 结构修饰 硝酸酯 偶联物 抗肿瘤

广州中医药大学"双一流"与高水平大学学科协同创新团队项目

2021xk87

2024

中国新药杂志
中国医药科技出版社 中国医药集团总公司 中国药学会

中国新药杂志

CSTPCD北大核心
影响因子:1.039
ISSN:1003-3734
年,卷(期):2024.33(7)
  • 25